NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions

Carcinoma, Non-Small-Cell LungUrothelial CarcinomaMalignant MelanomaHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

CAN04

Administered intravenously

DRUG

Pembrolizumab

Administered intravenously

DRUG

Carboplatin

Administered intravenously

DRUG

Pemetrexed

Administered intravenously

Trial Locations (3)

Florida Cancer Specialists & Research Institute, Lake Mary

University of Colorado Cancer Center, Aurora

Hospital of The University of Pennsylvania, Philadelphia